Related Experiment Video
Updated: Jan 7, 2026

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus MRSA Infection
Published on: September 1, 2023
Aluminium adjuvants and childhood health: a call for science
Guillemette Crépeaux1, Jeremy R Hammond2, Jonathan B Handley3
1Univ Paris Est Créteil, INSERM, IMRB, Créteil F-94010, France; Ecole Nationale Vétérinaire d'Alfort, EnvA, IMRB, Maisons-Alfort F-94700, France.
Insights
Early-life exposure to Aluminium (Al)-adjuvanted vaccines showed no increased risk for 50 chronic diseases in a large Danish study. However, critical flaws in methodology and transparency raise concerns about the study's conclusions on Al-Based Adjuvant safety.
Area of Science:
- Vaccine Adjuvant Safety
- Toxicology
- Epidemiology
Background:
- Aluminium (Al)-based adjuvants (ABA) are widely used in vaccines.
- Concerns persist regarding potential long-term health effects of ABA exposure.
- A recent study by Andersson et al. (2025) investigated ABA safety in a large cohort.
Purpose of the Study:
- To critically evaluate the methodological rigor and conceptual underpinnings of the Andersson et al. (2025) study on ABA safety.
- To assess the validity of conclusions drawn regarding the association between early-life ABA exposure and chronic disease risk.
Main Methods:
- Critical review of the methodology employed in the Andersson et al. (2025) study.
- Analysis of cohort design, statistical analysis, and reporting of potential conflicts of interest.
- Evaluation of the study's understanding of Aluminium toxicology.
Main Results:
- The Andersson et al. (2025) study reported no association between early-life ABA exposure and 50 chronic diseases.
- Significant methodological and conceptual flaws were identified in the study.
- Weaknesses include limited toxicological understanding, cohort design issues, and insufficient transparency.
Conclusions:
- The identified flaws prevent definitive conclusions on ABA safety, especially concerning neurodevelopmental and autoimmune outcomes.
- The study's findings are not sufficiently robust to be considered reassuring evidence of ABA safety.
- There is a critical need for more rigorous, transparent, and scientifically sound research on ABA safety.
Abstract:
In July 2025, Andersson et al. reported in Annals of Internal Medicine that early-life exposure to Aluminium (Al)-adjuvanted vaccines was not associated with increased risk of 50 chronic diseases, based on a Danish cohort of 1.2 million children. While widely cited as reassuring evidence of Al-Based Adjuvant (ABA) safety, closer scrutiny reveals major methodological and conceptual flaws. Specifically, the study demonstrates limited understanding of Al toxicology, weaknesses in cohort design and statistical analysis, and insufficient transparency regarding potential conflicts of interest. We argue that these shortcomings prevent meaningful conclusions about ABA safety, particularly in relation to neurodevelopmental and autoimmune outcomes, and highlight the need for more rigorous, transparent, and scientifically grounded investigations.
Related Concept Videos
Types of Toxins
Air pollutants, primarily gases, pose significant threats to respiratory health, leading to conditions like hypoxia, lung cancer, and in extreme cases, death.
Environmental pollutants like...
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Teratogenicity
The Periodic Table and Organismal Elements
Periodic Table Provides Information...
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Toxic Reactions: Overview
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...

